Report of the Expert Committee for the Selection and Inclusion of Medicines in the Pan American Health Organization Strategic Fund – July 2013
Abstract
Executive Summary
The inaugural meeting of the Expert Committee for the Selection and Inclusion of Medicines in the Pan American
Health Organization Strategic Fund was held at the Headquarters of the Pan American Health Organization
(PAHO) in Washington, D.C., on 17-18 July 2013.
Experts from the Region of the Americas where convened to provide recommendations to the PAHO
Director for the potential inclusion of eight medicines in the Strategic Fund Medicine List. The names of the
members of the Expert Committee and their corresponding declarations of interests are provided in the full
report.
The Expert Committee reviewed applications for eight medicines for the treatment of noncommunicable
diseases, such as cardiovascular disease and cancer, and immunosuppressive medicines used to prevent graft
rejection after transplantation. The Committee evaluated the presented evidence regarding effectiveness,
safety and cost in comparison to alternative treatments already present in the Strategic Fund Medicine List.
The Expert Committee issued the following recommendations to the PAHO Director:
Include six medicines (chlorthalidone, clopidogrel, losartan, mycophenolate mofetil, tacrolimus and
trastuzumab) in the Strategic Fund Medicine List. Reject two medicines (lisinopril and sirolimus) in the Strategic Fund Medicine List
PAHO in its function as the secretariat of the Expert Committee prepared the medicine dossiers at the
request of Member States and/or PAHO Technical Units. The product dossiers and a summary of the committee’s
evaluations are available in the full report.
The Committee worked exclusively on evaluating the applications for potential inclusion in the Strategic
Fund Medicine List, which enabled PAHO to adequately respond to the needs of PAHO Member States. Due
to this specific function and objective, this committee does not seek to replace or complement the work
performed by WHO in developing the Essential Medicine List or by Member State pharmacotherapeutic committees
who decide to include or exclude medicines from national essential medicine lists. As a result, the
recommendations issued by this Committee should not be utilized as references for the development of other
essential medicine lists or treatment guidelines.
Subject
Collections
Related items
Showing items related by title, author, creator and subject.
-
Recommendations of the Expert Committee for the Selection and inclusion of Medicines in the PAHO’s Strategic Fund 2015. Washington
Pan American Health Organization (Washington, D.C, PAHO, 2016)The PAHO Regional Revolving Fund for Strategic Public Health Supplies (hereinafterreferred to as the PAHO Strategic Fund or the Strategic Fund), was created in 1999 by the then Director of PAHO at the request of Member ... -
Strategic Fund Annual Report 2019. Improving Access to Quality Medicines and Health Technologies in the Americas
Pan American Health Organization; Health Systems and Services (HSS) (Washington, D.C., PAHO, 2020-07-13)In 2000, the Pan American Health Organization (PAHO) established the Strategic Fund to improve access to safe, efficacious, and high-quality medicines and other health supplies. This increased access would inevitably ... -
Strategic Fund. Annual Report 2017. Access to quality medicines and health
Pan American Health Organization (Washington, D.C., PAHO, 2018-09)The Strategic Fund is a regional technical cooperation mechanism for pooled procurement of essential medicines and strategic public health supplies in the Americas. The Strategic Fund was created in 2000 by the Pan American ...